DRDO Developed COVID19 Drug Approved by DCGI for Emergency Use

New Delhi: The Drugs Controller General of India (DCGI) has approved an anti-COVID oral drug on Saturday, which was developed by DRDO, for emergency use as an adjunct therapy in moderate to severe infected Covid19 patients.

Drug, 2-DG dose comes in powder form in sachet and is taken orally by dissolving it in water.

According to Defence Research and Development Organisation (DRDO), clinical trials of the drug 2-deoxy-D-glucose (2-DG) showed that it helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence. The whish was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of DRDO, in collaboration with Dr Reddy’s Laboratories in Hyderabad.

DRDO said, “On May 01, DCGI granted permission for emergency use of this drug as an adjunct therapy in moderate to severe COVID-19 patients. Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country,”

DRDO further said that the  “Drug accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally-infected cells makes this drug unique.”

Read Also…

Daily Quote

More Hyderabad News

1 2 3 4 5

You can get instant news and articles from Hyderabad Post

Click to Like/Follow/Subscribe us on Facebook – Twitter – Telegram – Instagram – WhatsApp – YouTube – Reddit – Koo

More National, Global News

1 2 3 4 5

1 2 3 4 5

You can get instant news and articles from Hyderabad Post

Click to Like/Follow/Subscribe us on Facebook – Twitter – Telegram – Instagram – WhatsApp – YouTube – Reddit – Koo